1 week Ago By Defense World Staff
Prudential Financial Inc. trimmed its holdings in shares of Royalty Pharma plc ( NASDAQ:RPRX – Free Report ) by 4.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
The fund owned 18,360 shares of the biopharmaceutical company’s stock after selling 955 shares during the quarter. Prudential Financial Inc.’s holdings in Royalty Pharma were worth $488,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the stock. Fox Run Management L.L.
C. increased its holdings in shares of Royalty Pharma by 41.3% during the 4th quarter.
Fox Run Management L.L.C.
now owns 55,062 shares of the biopharmaceutical company’s stock valued at $1,405,000 after acquiring an additional 16,084 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Royalty Pharma in the fourth quarter valued at approximately $3,145,000. Hillsdale Investment Management Inc.
raised its position in shares of Royalty Pharma by 2.5% in the fourth quarter. Hillsdale Investment Management Inc.
now owns 24,250 shares of the biopharmaceutical company’s stock valued at $619,000 after purchasing an additional 600 shares during the period. Sei Investments Co. boosted its holdings in shares of Royalty Pharma by 58.
1% during the 4th quarter. Sei Investments Co. now owns 109,557 shares of the biopharmaceutical company’s stock worth $2,795,000 after buying an additional 40,271 shares during the period.
Finally, American Century Companies Inc. grew its stake in Royalty Pharma by 5.8% in the 4th quarter.
American Century Companies Inc. now owns 67,160 shares of the biopharmaceutical company’s stock valued at $1,713,000 after buying an additional 3,671 shares during the last quarter. 54.
35% of the stock is currently owned by institutional investors. Wall Street Analysts Forecast Growth A number of research firms have issued reports on RPRX. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th.
Citigroup restated a “buy” rating on shares of Royalty Pharma in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.
com, the stock presently has an average rating of “Buy” and an average target price of $41.60. Royalty Pharma Stock Up 4.
6 % Shares of RPRX opened at $32.27 on Thursday. Royalty Pharma plc has a 52 week low of $24.
05 and a 52 week high of $34.20. The firm has a market capitalization of $18.
60 billion, a P/E ratio of 22.26, a P/E/G ratio of 2.31 and a beta of 0.
50. The company has a 50-day simple moving average of $32.49 and a 200-day simple moving average of $29.
08. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.
44 and a current ratio of 1.44. Royalty Pharma ( NASDAQ:RPRX – Get Free Report ) last announced its quarterly earnings data on Tuesday, February 11th.
The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.
16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.
94%. On average, equities research analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current year.
Royalty Pharma Profile ( Free Report ) Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Stories Five stocks we like better than Royalty Pharma Investing in Travel Stocks Benefits Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore Are Penny Stocks a Good Fit for Your Portfolio? Are Tariffs Threatening Disney’s Comeback Story? Golden Cross Stocks: Pattern, Examples and Charts Is Alphabet a Generational Buying Opportunity at These Levels? Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter .
.
